（二）业绩预告情况 经财务部门初步测算： 1、2025 年前三季度实现营业收入约 42,800 万元，较上年同期增长 10.55%； 证券代码：688089 证券简称：嘉必优 公告编号：2025-075 嘉必优生物技术（武汉）股份有限公司 关于 2025 年前三季度业绩预增的自愿性披露公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、本期业绩预告情况 （一）业绩预告期间 2025 年 1 月 1 日至 2025 年 9 月 30 日。 2、2025 年前三季度实现归属于母公司所有者的净利润约 12,900 万元，较上 年同期增长 53.77%； 3、2025 年前三季度实现归属于母公司所有者的扣除非经常性损益的净利润 约 11,500 万元，较上年同期增长 75.41%。 （三）本次业绩预告相关财务数据未经注册会计师审计。 二、上年同期业绩情况和财务状况 1、2024 年前三季度营业收入：38,714.79 万元； 2、2024 年前三季度利润总额：9,428.58 万元； 3、2024 年前三季度归属于母公司所有 ...

Core Viewpoint - The company Jia Bi You (688089.SH) has announced a significant increase in net profit for the first three quarters, indicating strong performance driven by sales growth in domestic markets and improved operational efficiency [1] Group 1: Financial Performance - The net profit attributable to the parent company for the first three quarters is approximately 129 million yuan, representing a year-on-year increase of 53.77% [1] - The increase in revenue is primarily due to higher sales volumes of ARA and algal oil DHA products to domestic customers [1] Group 2: Operational Efficiency - Profit growth is attributed to increased revenue, enhanced production efficiency, and optimization of product and customer structures, which have collectively improved the company's profitability [1]

Core Insights - The company, Jia Bi You (688089.SH), reported a revenue of approximately 428 million yuan for the first three quarters of 2025, representing a year-on-year growth of 10.55% [1] - The net profit attributable to the parent company for the same period is approximately 129 million yuan, showing a significant increase of 53.77% year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses is about 115 million yuan, reflecting a substantial growth of 75.41% compared to the previous year [1] Revenue Analysis - The increase in revenue is primarily attributed to the rise in sales of ARA and DHA products to domestic customers [1] Profitability Factors - The profit growth is driven by the increase in revenue, enhanced production efficiency, and optimization of product and customer structures, which have collectively improved the company's profitability [1]

报告期内公司营业收入增加主要系国内客户ARA和藻油DHA产品销量增加所致；利润增加主要系营业 收入增加，同时公司生产效率提升，叠加产品结构和客户结构优化，提升了公司的盈利能力。 格隆汇10月15日丨嘉必优(688089.SH)公布，经财务部门初步测算：1、2025年前三季度实现营业收入约 4.28亿元，较上年同期增长10.55%；2、2025年前三季度实现归属于母公司所有者的净利润约1.29亿 元，较上年同期增长53.77%；3、2025年前三季度实现归属于母公司所有者的扣除非经常性损益的净利 润约1.15亿元，较上年同期增长75.41%。 ...

Core Insights - The company reported a revenue of approximately 428 million yuan for the first three quarters of 2025, representing a year-on-year growth of 10.55% [1] - The net profit attributable to the parent company's shareholders was approximately 129 million yuan, reflecting a year-on-year increase of 53.77% [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was about 115 million yuan, showing a year-on-year growth of 75.41% [1] Revenue Analysis - The increase in revenue was primarily driven by higher sales volumes of ARA and algal oil DHA products to domestic customers [1] Profitability Factors - The profit increase was attributed to the rise in revenue, enhanced production efficiency, and optimization of product and customer structures, which improved the company's profitability [1]

Core Viewpoint - The company, Jia Bi You (688089), announced a significant increase in its performance for the first three quarters, with notable growth in both revenue and net profit [1] Financial Performance - The company achieved an operating revenue of approximately 428 million yuan, representing a year-on-year increase of 10.55% [1] - The net profit attributable to the parent company was around 129 million yuan, reflecting a substantial year-on-year growth of 53.77% [1] Revenue Drivers - The increase in operating revenue was primarily driven by higher sales of ARA and algal oil DHA products to domestic customers [1]

Core Viewpoint - The article emphasizes the rising importance of biomanufacturing as a strategic and innovative field, which is seen as a new growth point that can drive industrial structure optimization and economic transformation. The release of the "2025 China Synthetic Biomanufacturing Industry Development White Paper" highlights the current state, trends, and challenges of the biomanufacturing industry in China [1]. Group 1: Current State and Trends - The white paper provides an overview of the global biomanufacturing industry, including its development status and trends [5]. - It compares the biomanufacturing sectors of China and the United States, highlighting competitive dynamics [5]. - Future development trends in biomanufacturing are discussed, indicating potential growth areas [5]. Group 2: Policy Landscape - The report outlines major policies affecting biomanufacturing both domestically and internationally for the years 2024-2025 [5]. - It details foreign biomanufacturing industry policies and their implications for the sector [5]. - Domestic policies related to biomanufacturing are also analyzed, providing insights into regulatory frameworks [5]. Group 3: Industry Map and Applications - The white paper presents a comprehensive map of the Chinese biomanufacturing industry, identifying key players and their roles [5]. - It analyzes the biomanufacturing industry chain and key application areas, including pharmaceuticals, food, personal care, agriculture, chemicals, materials, and energy [5][6]. - Specific applications of biomanufacturing in various sectors are highlighted, showcasing its versatility and potential impact [5]. Group 4: Key Enterprises and Investment Landscape - The report identifies ten leading enterprises in the Chinese biomanufacturing industry, providing insights into their operations and market positions [6]. - It summarizes the strategic directions of 15 listed companies in synthetic biology, indicating their focus areas and growth strategies [6]. - The investment landscape for synthetic biology in China is examined, detailing funding trends and opportunities from 2024 to mid-2025 [6]. Group 5: Challenges and Recommendations - The white paper discusses the challenges faced by the biomanufacturing industry in China, including technological, regulatory, and market-related issues [6]. - It offers targeted policy recommendations to address these challenges, aiming to support the sustainable development of the biomanufacturing sector [6].

每经AI快讯，嘉必优（SH 688089，收盘价：25.79元）10月9日晚间发布公告称，截至2025年9月30日， 公司通过上海证券交易所交易系统以集中竞价交易方式累计回购公司股份约72万股，占公司总股本约 1.68亿股的比例为0.43%，最高成交价为28.58元/股，最低成交价为25.46元/股，累计成交总金额约为 1962万元。 每经头条（nbdtoutiao）——与美元脱钩后，暴涨102倍，揭秘黄金疯涨背后神秘的"无形之手"！专家： 推动金价上涨的逻辑没有变 （记者 王晓波） 截至发稿，嘉必优市值为43亿元。 2024年1至12月份，嘉必优的营业收入构成为：人类营养占比94.27%，动物营养占比2.96%，其他业务 占比2.4%，个人护理及化妆品占比0.38%。 ...

关于第二期以集中竞价交易方式回购公司股份的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 | 回购方案首次披露日 | 2025 年 月 | 1 | 25 | 日 | | --- | --- | --- | --- | --- | | 回购方案实施期限 | 董事会审议通过后 12 个月内 | | | | | 预计回购金额 | 1,500 万元（含）-3,000 | | | 万元（含） | | 回购用途 | □减少注册资本 用于员工持股计划或股权激励 | | | | | | □用于转换公司可转债 | | | | | | □为维护公司价值及股东权益 | | | | | 累计已回购股数 | 715,458 | 股 | | | | 累计已回购股数占总股本比例 | 0.43% | | | | | 累计已回购金额 | 19,624,295.97 元 | | | | | 实际回购价格区间 | 25.46 元/股~28.58 元/股 | | | | 重要内容提示： 一、回购股份的基本情况 2025 年 1 月 24 日，公司召开 ...

Core Insights - The Chinese health food industry is experiencing a structural transformation characterized by "inventory reshuffling and weakened growth," moving away from the era of broad-based growth due to regulatory upgrades and evolving consumer concepts [2][10] Industry Overview - In the first half of 2025, the online market for health food reached a sales figure of 60.41 billion yuan, with a year-on-year growth rate of 16.2%, indicating the sector's competitive intensity [2] - Major companies are facing declining revenues, with inventory turnover days increasing, signaling a challenging environment for traditional growth models [2][10] Company Performance - The vitality ranking of health food companies shows significant performance disparities, with innovative companies gaining a premium [4][5] - Key players like健合集团 reported a revenue of 7.02 billion yuan, with a 71.7% increase in revenue from emerging Asian markets, highlighting successful global strategies [5] - 仙乐健康, a leading CDMO, achieved a revenue of 2.042 billion yuan (+2.57%), with a remarkable 200% growth in private traffic contributing to its success [7] - 汤臣倍健's second-quarter net profit grew by 71.4%, indicating effective inventory management and operational efficiency [9] Market Trends - The health food sector is witnessing structural growth, with significant differentiation in performance across companies and product categories [5] - Categories such as cardiovascular health (37.4% growth), bone health (34.9% growth), and women's health (26.0% growth) are emerging as key growth drivers [10] - The shift towards new consumption channels, including live streaming and private domains, is becoming crucial for enhancing customer loyalty and combating rising public traffic costs [10][13] Future Outlook - The industry is expected to continue its trend of differentiation, with a focus on precision, technology, and globalization as core competitive strategies [10][12] - Companies are encouraged to explore overseas markets, particularly in Southeast Asia and Latin America, to leverage demographic advantages and growth potential [13] - The competition is entering a new phase centered on quality improvement, with long-term strategic focus and technological accumulation being vital for success [13]